Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management
Open Access
- 13 December 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 5, 344
Abstract
Spitzoid neoplasms are a distinct group of melanocytic proliferations characterized by epithelioid and/ or spindle shaped melanocytes. Intermediate forms that share features of both benign Spitz nevi (SN) and Spitz melanoma, i.e., malignant Spitz tumor (MST) represent a diagnostically and clinically challenging group of melanocytic lesions. A multitude of descriptive diagnostic terms exist for these ambiguous lesions with atypical Spitz tumor (AST) or Spitz tumor of uncertain malignant potential (STUMP) just naming two of them. This diagnostic gray zone creates confusion and high insecurity in clinicians and in patients. Biological behavior and clinical course of this intermediate group still remains largely unknown, often leading to difficulties with uncertainties in clinical management and prognosis. Consequently, a better stratification of Spitzoid neoplasms in benign and malignant forms is required thereby keeping the diagnostic group of AST/STUMP as small as possible. Ancillary diagnostic techniques such as immunohistochemistry, comparative genomic hybridization, fluorescence in situ hybridization, next generation sequencing, micro RNA and mRNA analysis as well as mass spectrometry imaging offer new opportunities for the distinct diagnosis, thereby allowing the best clinical management of Spitzoid neoplasms. This review gives an overview on these additional diagnostic techniques and the recent developments in the field of molecular genetic alterations in Spitzoid neoplasms. We also discuss how the recent findings might facilitate the diagnosis and stratification of atypical Spitzoid neoplasms and how these findings will impact the diagnostic work up as well as patient management. We suggest a stepwise implementation of ancillary diagnostic techniques thereby integrating immunohistochemistry and molecular pathology findings in the diagnosis of challenging ambiguous Spitzoid neoplasms. Finally, we will give an outlook on pending future research objectives in the field of Spitzoid melanocytic lesions.Keywords
Funding Information
- Maastricht Universitair Medisch Centrum
This publication has 123 references indexed in Scilit:
- A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 ExpressionAmerican Journal of Surgical Pathology, 2012
- Imaging Mass Spectrometry—A New and Promising Method to Differentiate Spitz Nevi From Spitzoid Malignant MelanomasThe American Journal of Dermatopathology, 2012
- Germline mutations in BAP1 predispose to melanocytic tumorsNature Genetics, 2011
- miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesionsBritish Journal of Cancer, 2011
- Protein signatures for survival and recurrence in metastatic melanomaJournal of Proteomics, 2011
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature, 2008
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- Mutations of the BRAF gene in human cancerNature, 2002
- Eosinophilic globules in the Spitz nevusJournal of the American Academy of Dermatology, 1982